Safety & Efficacy of Extended Longevity Protocol

NCT05296993 | Unknown Phase 2

• 1 other identifier: TD-EL-001
• Study Type: interventional
• Target: 15
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to quantifiably determine if the Extended Longevity Protocol has a significant clinical effect on epigenetic age.

Conditions

Aging

Outcome Measures

Primary Outcomes (2)

• Epigenetic Age

  Serum epigenetic aging test

  Testing will compare the change in results from baseline to 3 months

• Epigenetic Age

  serum epigenetic aging test

  Testing will compare the change in results after completion of intervention with baseline

Study Arms (1)

Extracts

EXPERIMENTAL

The ingredients found in these serums are all naturally occurring ingredients extracted from a variety of plant species: Pinetonal, Thyvolve, Telogenic, Sentophagy, Inflasolve, Stemegenis, and CMEnhance

Dietary Supplement: Extracts found in the Extended Longevity supplements

Interventions

Extracts found in the Extended Longevity supplements DIETARY_SUPPLEMENT

Ingredients found in these serums are all naturally occurring, and extracted from a variety of plant species.

Extracts

Eligibility Criteria

• Age: 55 Years - 75 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Men and 7 Women
• Must between 55-75 years old
• Patient must be able to comply with treatment plan and laboratory tests
• Patients must have adequate immune system function, with no known immunodeficiency disease

You may not qualify if:

• Neoplastic cancer within 5 years prior to screening, except for cutaneous basal cell or squamous cell cancer resolved by excision
• No immune system issues or immunodeficiency disease
• No history of viral illness which could be reactivated by immune downregulation
• Presence of clinically significant acute or unstable cardiovascular and cerebrovascular (stroke) disease
• Diagnosis of a transient ischemic attack in the 6 months prior to screening
• Patients infected with hepatitis, C or HIV
• Patients with Body Mass Index (BMI) \> 40 kg/m2
• Presence of active infection
• Any other illness, psychiatric disorder, alcohol or chemical dependence that in the opinion of the investigator would render a patient unsuitable to participate in the study
• Unable or unwilling to provide required blood sample for testing

Sponsors & Collaborators

• TruDiagnostic: lead

Study Sites (1)

Quantum Functional Medicine

Carlsbad, California, 92008, United States

Location

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: PREVENTION
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 4, 2022
• First Posted: March 25, 2022
• Study Start: May 25, 2021
• Primary Completion: December 1, 2022
• Study Completion: December 1, 2023
• Last Updated: May 11, 2022

Record last verified: 2022-05

Locations

US (1)